Soleno Therapeutics, Inc. (SLNO) Dividend History

Company News

• Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome

  Soleno Therapeutics announced the validation of its Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for its drug Diazoxide Choline Prolonged-Release Tablets (DCCR) to treat hyperphagia in Prader-Willi syndrome patients.

  GlobeNewswire Inc.
• Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight

  The obesity market is projected to grow from 2024 to 2034 due to the rising prevalence of obesity and the extensive pipeline of emerging drugs with improved safety profiles. The article discusses different types of obesity, including hypothalamic, pediatric, POMC deficiency, and syndromic/monogenic obesity, and the current treatment landscape and pipeline for each.

  GlobeNewswire Inc.

  Featured Companies: AARD ALT LLY PFE RYTM
• Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

  Soleno Therapeutics, a clinical-stage biopharmaceutical company, announced that it will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024.

  GlobeNewswire Inc.
• Soleno Therapeutics enters agreement to sell $150 million in stock By Investing.com - Investing.com Canada

  Soleno Therapeutics, a medical device company, has entered into an agreement with Jefferies LLC to potentially sell up to $150 million of its common stock. The new funding option aims to bolster the company's financial flexibility and support its ongoing operations and strategic initiatives.

  Investing.com

  Featured Companies: JEF
• Soleno therapeutics exec sells over $90k in stock By Investing.com - Investing.com

  Soleno Therapeutics executive Kristen Yen sold over $90,000 worth of company stock to cover tax withholding obligations related to the vesting of restricted stock units. The transactions do not necessarily reflect the company's future performance.

  Investing.com